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Introduction. Mast cell (MC) leukemia (MCL) is extremely rare. We present a case of MCL diagnosed concomitantly with acute
myeloblastic leukemia (AML). Case Report. A 41-year-old woman presented with asthenia, anorexia, fever, epigastralgia, and
diarrhea. She had a maculopapular skin rash, hepatosplenomegaly, retroperitoneal adenopathies, pancytopenia, 6% blast cells
(BC) and 20% MC in the peripheral blood, elevated lactate dehydrogenase, cholestasis, hypoalbuminemia, hypogammaglob-
ulinemia, and increased serum tryptase (184 μg/L). )e bone marrow (BM) smears showed 24% myeloblasts, 17% promyelocytes,
and 16% abnormal toluidine blue positive MC, and flow cytometry revealed 12% myeloid BC, 34% aberrant promyelocytes,
a maturation blockage at the myeloblast/promyelocyte level, and 16% abnormal CD2−CD25+MC.)e BMkaryotype was normal,
and the KIT D816V mutation was positive in BM cells. )e diagnosis of MCL associated with AML was assumed. )e patient
received corticosteroids, disodium cromoglycate, cladribine, idarubicin and cytosine arabinoside, high-dose cytosine arabinoside,
and hematopoietic stem cell transplantation (HSCT). )e outcome was favorable, with complete hematological remission two
years after diagnosis and one year after HSCT. Conclusions. )is case emphasizes the need of an exhaustive laboratory evaluation
for the concomitant diagnosis of MCL and AML, and the therapeutic options.
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1. Introduction
Mastocytoses are rare neoplasms defined by an abnormal
expansion/accumulation of clonal mast cells (MC) in one or
more organs or tissues [1, 2].)e 2016 revision to the “World
Health Organization (WHO) Classification of Tumors of the
Hematopoietic and Lymphoid Tissues” divides the disease
into cutaneous mastocytosis (CM), systemic mastocytosis
(SM), and localized mast cell tumors [1, 2]. Cutaneous
mastocytosis includes maculopapular CM, also known as
urticaria pigmentosa, diffuse CM, and mastocytoma of
skin. Systemic mastocytosis is further divided into indolent SM
(ISM), smoldering SM (SSM), and advanced SM variants; the
latter includes aggressive SM (ASM),mast cell leukemia (MCL),
and SM with associated hematological neoplasm (SM-AHN),
previously known as SM with associated clonal hematological
non-MC lineage disease (SM-AHNMD), and mast cell leu-
kemia (MCL) [1, 2]. Associated hematological neoplasms may
consist of myelodysplastic syndromes (MDS), myeloprolifer-
ative neoplasms (MPN), myelodysplastic/myeloproliferative
neoplasms (MDS/MPN), and also acute myeloid leukemia
(AML).
In the last years, serum tryptase levels [3], immuno-
phenotypic characterization of BM mast cells by flow
cytometry (FCM) [4, 5] and KITmutation analysis [6], have
proved to be useful for establishing the diagnosis, sub-
classifying and evaluating the prognosis of SM, adding
important information to conventional cytomorphology
and histopathology. Mast cells, and often other BM cells,
from most patients with SM usually harbor the activating
KIT D816V mutation. In addition, they regularly have ab-
normal morphology, from atypical MC type I, usually ob-
served in ISM, to more immature atypical MC type II and
metachromatic blasts, more frequently found in ASM and
MCL, and they exhibit abnormal phenotypic features, from
which the most frequent and more extensively studied are
positivity for CD25 and/or CD2.
Mast cell leukemia accounts for <1% of all mastocytosis,
it may appear de novo or secondary to a previously di-
agnosed MC disorder (usually ASM or SM-AHN), and it
may associate with other hematological neoplasms (MCL-
AHN) [7, 8]. Diagnosis is based on the presence of ≥20%
atypical MC in the bone marrow (BM) and/or ≥10% in the
peripheral blood (PB); an aleukemic variant with less than
10% of MC in the PB also exists. )e European/American
Consensus Group onMastocytosis (EU/US-CGM) proposed
a subclassification that distinguishes acute from chronic
MCL based on the presence or absence of organ damage,
respectively [9]. )e neoplastic MC usually have an im-
mature morphology and an abnormal immature and/or
activated phenotype, although they often fail to have the
abnormal CD2+CD25+ pattern encountered in most forms
of SM; in addition, the KIT D816V mutation is detected in
less than 50% of cases, and most patients have a normal
karyotype. Symptoms of MC activation and involvement of
the liver, spleen, peritoneum, digestive tract, and bones are
relatively frequent, and skin lesions occur in only 1/3 of the
cases. Treatment usually fails, and the median survival time
is short. Due in part to the rarity, no standard therapy exists,
and the role of hematopoietic stem cell transplantation
(HSCT) needs further investigation.
Distinguishing MCL from SM associated with AML
and from myelomastocytic leukemia (MML) is a challenge
and requires a detailed laboratory investigation using
cytology, cytochemistry, histopathology, immunohisto-
chemistry, immunophenotypic, and genetic approaches
[9–16]. )e EU/US-CGM and the European Competence
Network on Mastocytosis (ECNM) have recently proposed
the criteria to establish the differential diagnosis between
these entities [9].
We present a case of MCL diagnosed concomitantly to
AML, given emphasis on the role of the laboratory exams,
specially immunophenotyping and genetic testing, in estab-
lishing the differential diagnosis with MML. In addition, we
compare the clinical and laboratory features of our patient
with those described in previously published series of patients
with MCL, ISM, ASM, and SM-ANH. Finally, we describe the
success of the therapeutic strategy used in this patient, which
included cladribine, anthracycline in combination with cy-
tosine arabinoside, and HSCT.
2. Case Report
A 41-year-old Caucasian woman was admitted at the hos-
pital with one-month history of asthenia, anorexia, fever,
abdominal pain, early postprandial surfeit, and diarrhea. She
had past history of an intermittent migratory pruritic
maculopapular rash and mild episodes of flushing that had
never been investigated, hypothyroidism, an anxiety dis-
order, and emotional instability, and she had smoked 20
cigarettes a day since the age of 13. )ere was no history of
allergies or other pathologies.
When first observed at the hospital, she had a fever,
a dark spot on the tongue, a slightly pruritic brownish
erythematous maculopapular skin rash predominantly in
the upper limbs, hepatomegaly (the left lobe of liver
was enlarged and extended to epigastric region and the
right lobe was four fingers below the right costal margin
in the midclavicular line), and splenomegaly (5 fingers
below the left costal margin). )ere was no peripheral
lymphadenopathy.
Peripheral blood counts revealed pancytopenia: hemoglo-
bin (Hg) 11.0 g/dl (normal range 12.0–15.0), platelets 16×109/L
(normal range 150–400), and white blood cells (WBC)
4.25 ×109/L (normal range 4.0–11.0) with 7.0% neutrophils
(0.3 ×109/L) (normal range 2.0–7.5), 6% blast cells (BC),
and 20% of cells with metachromatic cytoplasmic granules
that were initially classified as basophils by morphology
(Figure 1), but whose immunophenotypic study subsequently
revealed them to be an abnormal immature MC.
Serumbiochemistry showed elevated lactate dehydrogenase
(369U/L, normal range 135–214U/L) and abnormal hepatic
tests with a cholestatic pattern: total bilirubin 1.2mg/dl
(normal range: 0.2–1.0), direct bilirubin 1.1mg/dl (normal
range: 0.0–0.2), indirect bilirubin 1.14mg/dl (normal range:
0.0–1.0), alanine transaminase 90U/L (normal range: 10–30),
aspartate transaminase 36U/L (normal range: 10–30),
alkaline phosphatase 731U/L (normal range: 32–104), and
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gamma-glutamyl transferase 638U/L (normal range: 6–39).
)ere was also hypoalbuminemia (serum albumin 32 g/L,
normal range: 35–50) and hypogammaglobulinemia (serum
IgG 522mg/dl, normal range: 793–1590; IgA 127mg/dl,
normal range: 114–457; IgM 170 mg/dl, normal range:
29–226). Serum tryptase levels were markedly increased
(184μg/L, normal range< 13μg/L). Calcium and phosphate
serum levels were normal, as did renal function tests. Co-
agulation tests, including prothrombin time, activated partial
thromboplastin time, and fibrinogen levels, were within the
normal range. Serological tests for hepatitis B andC viruses and
human immunodeficiency virus type 1 and 2 were negative.
Bone marrow smears showed 24% myeloperoxidase
(MPO) positive BC, 17% promyelocytes, 4% myelocytes, 3%
metamyelocytes + neutrophils (AML-M2 classification by
cytomorphology), 30% erythroid lineage, and 16% mor-
phologically abnormal toluidine blue positiveMC (Figure 2).
)ese cells had variable morphological features, from
atypical MC type I and II to metachromatic blasts.)ere was
no BM eosinophilia, or evidence of myelodysplasia. Flow
cytometry of the BM aspirate revealed 12% of CD45+ (low),
CD117+, CD34+ myeloid precursor cells (MPC) also
expressing CD123, HLA-DR (high), CD13, CD33, CD65
(low), and CD25 (low, in part of the cells) but lacking CD10,
CD15, CD16, CD2, CD30, and FcεRI/IgE; 5% of CD45+
(low), CD117+, CD34− MC precursors (MCP), also being
positive for CD123 (high), CD13, CD33, CD65 (low), CD25,
CD30, FcεRI/IgE, and HLA-DR (high), and lacking CD10,
CD15, CD16, and CD2; 34% promyelocytes with an aberrant
phenotype (CD45+, CD34−, CD117+, CD13+low, CD33+,
CD65+; CD15+, MPO+, and CD2, CD10, CD11b, CD16,
CD25, CD30, FcεRI/IgE, and HLA-DR negative); a matu-
ration blockage at the promyelocyte level, as revealed by
an abnormal CD11b/CD13/CD16 maturation pattern, with
<1% of CD16+CD10+ mature neutrophils; and 13% of ab-
normal CD45+, CD34−, CD117+high MC with a relatively
immature (CD123+high, FcεRI/IgE+ low, and HLA-DR+high),
activated (CD63+, CD69+), and aberrant (CD2−, CD25+,
and CD30+) immunophenotype (Figure 3). Cytoplasmic
carboxypeptidase and surface CD203 were also positive
(data not shown). In addition, FCM performed in PB,
showed 3% CD45+low, CD117+, CD34+ MPC, and 21% of
CD45+low, CD117+, CD34− MCP, which were phenotyp-
ically similar to the correspondent BM cell populations, at
least for the cell surface markers tested, but not CD45+,
CD34−, and CD117+ high MC (Figure 4).
Bone marrow trephine biopsy revealed a hypercellular
marrow with increased proportions of immature MPO+
myeloid cells and morphologically atypical CD117+ fusiform
MC forming perivascular dense aggregates, and grade 2
fibrosis (Figure 5). Skin biopsy was not performed.
Cytogenetic analyses of at least 20 Giemsa-banded BM cell
metaphases obtained from unstimulated 24 hour cultures
disclosed a 46,XX karyotype, without numerical or structural
abnormalities. Genetic studies using probes for relevant targets,
including t(15;17) PML-RARA, t(8;21) RUNX1-RUNX1T1,
inv(16) CBFB-MYH11, and t(9,22) BCR-ABL, gave negative
results. Tests for FLT3 (FMS-like tyrosine kinase 3) andNPM-1
(Nucleophosmin-1) gene mutations were also negative. KIT
mutation at the codon 816 (D816V) (A7176T) was detected in
all sorted BM cell populations, except in T cells; BM cells
harboring theKITD816Vmutation includedMC, CD34+ cells,
CD34-HLA-DR-, CD34-HLA-DR+, and CD34-HLA-DR++
cells.
Abdominopelvic computerized tomography scan affirmed
hepatomegaly (18.5 cm) and mild splenomegaly (13 cm) with
small hypodense nodules (maximum diameter 10mm) and
revealed retroperitoneal adenopathies forming a conglomerate
extending from the lesser gastric curvature and involving
the large vessels; the largest adenopathy was in the hepatic-
duodenal ligament and had 2.4 cm of major diameter. )ere
was also a lamina of peritoneal liquid in pelvic cavitation.
Digestive endoscopy revealed slight reduced distensi-
bility of the gastric body, which had a congestive mucosa
Figure 1: Peripheral blood smears showing different types of morphologically abnormal mast cells. Leishman’s stain (a, 40x; b, 100x).
Circulating mast cells (MC) had variable morphological features, from metachromatic blasts of medium to large cell size, round to oval
shape, fine/immature nuclear chromatin, high nuclear : cytoplasmic ratio, and cytoplasmic metachromatic granules, to atypical MC type 2
with variable, sometimes spindle, cell shape, bilobated nucleus with fine to moderately condensed chromatin, variable nuclear : cytoplasmic
ratio, and hypogranulated cytoplasm. Please note that in spite of these heterogeneous morphological features, all the MC present in the
peripheral blood had an aberrant immature phenotype, corresponding to abnormal MC precursors (Figure 4).
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with foci of erythema, and the duodenum had a congestive
andmicronodular mucosa. Biopsies were not performed due
to severe thrombocytopenia. Skeleton radiography did not
reveal osteolytic lesions. )orax radiography had no evi-
dence of mediastinal enlargement, lung consolidations, or
pleural effusions.
According to the WHO criteria [1, 2], and to the con-
sensus recommendations of the EU/US-CGM and the ECNM
[9], the patient was diagnosed with KIT D816V+ MCL as-
sociated with AML with normal karyotype. She was imme-
diately started with oral corticosteroids (prednisolone,
60mg/day for one week, tapered to 20mg/day over 1 month,
and then maintaining 20mg/day) and disodium cromogly-
cate (200mg capsules, 4 times daily), and H1 (cetirizine,
10mg/day, orally) and H2 (ranitidine, 150mg twice a day,
orally) antihistamines, which ameliorate the symptomatology.
)en, she received two cycles of cladribine (0.14mg/kg/day,
administered over a 2-hour infusion for 5 days) with one
month of interval, and the serum tryptase levels transiently
decreased to 41 μg/L (Figure 6).
One month after, she maintained constitutional symp-
toms, hepatomegaly, and pancytopenia, and she developed
cutaneous and mucosal hemorrhage (petechial rash, epistaxis,
and spontaneous oral cavity bleeding), myalgia, and bone
pain. By that time, the serum tryptase serum levels had in-
creased to 123μg/L (Figure 6), and the BM aspirate showed
47.0% myeloblasts, 8% promyelocytes, and 7.0% MC. Bone
marrow FCM revealed 3% MPC (CD45+low, CD34+, CD117+,
FcεRI/IgE−, CD2−, and CD25−/+), 7% MCP (CD45+ low,
CD34−, CD117+, FcεRI/IgE+low, CD2−, and CD25+), 46% of
immature granulocytic cells (almost complete maturational
arrest at the promyelocyte stage), and 7% of CD45+,
CD34−, CD117+ high, CD2−, and CD25+ MC. Peripheral
blood counts were WBC 2.07×109/L, neutrophils 4.0%
(0.08×109/L), MC 41.0%, BC 9.0%; Hg 8.8 g/dl; and platelets
28×109/L. Flow cytometry studies performed in the PB showed
48% CD45+ low, CD117+, CD34−, FcεRI/IgE+low, CD25+,
CD2− MCP, 4% CD45+low, CD34+, CD117+, FcεRI/IgE−,
CD25−/+, CD2− MPC; once again, circulating CD45+,
CD34−, CD117+high, CD2−, CD25+ MC were not observed.
By that time, she received induction therapy for AML con-
sisting of two cycles of idarubicin (12mg/m2/day, intravenous,
for 3 days) and cytosine arabinoside (AraC) (100mg/m2/day,
intravenous, for 7 days), achieving hematological remission
and normal tryptase levels after the second induction course
(Figure 6). At that time, the BM smears were slightly
hypocellular with 1.3% of BC and noMC. Bone marrow FCM
studies detected 1.5% of CD117+ CD34+MPC, 54%maturing
granulocytic cells, from which 26% were promyelocytes, 53%
were metamyelocytes and myelocytes, and 21% were mature
neutrophils, and 0.03% were phenotypically abnormal MC
(0.02% CD117+ CD34− CD2− CD25−/+low, FcεRI/IgE+
MCP, and 0.01% CD117+high CD34−, CD2−, CD25+,
FcεRI/IgE+lowMC). Consolidation therapy performed in the
subsequent 2 months consisted of two courses of high-dose
AraC (2 g/m2, intravenous).
As complication of treatment she had bartholinite,
treated with piperacillin plus tazobactam, and
(a) (b)
(c)
Figure 2: Bone marrow smears showing myeloperoxidase positive blast cells and promyelocytes, and morphologically abnormal toluidine
blue positive mast cells. (a) Leishman. (b) Myeloperoxidase. (c) Toluidine blue staining.
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Figure 3: Continued.
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metronidazole; oral mucositis grade II controlled with
tramadol; febrile neutropenia with bacteremia by Escherichia
Coli treated with piperacillin plus tazobactam; pneumonia
without respiratory insuciency, which was responsive to
imipenem plus vancomycin, and pseudomembranous colitis
by Clostridium dicile, treated with metronidazole.
Two months after the second course of consolidation
chemotherapy, the patient received isogroup HLA-identical
related allogeneic HSCT from her sister (10/10 match)
(5.09×106/kg nonmanipulated peripheral blood CD34+ cells,
totalizing 322×106 CD34+ cells). e reduced-intensity con-
ditioning regimen included udarabine (30mg/m2/day for
5 days) and busulfan (4mg/kg/day for 2 days). As acute
complication, she had febrile neutropenia treated with
meropenem. On day 30 after HSCT, she had recovery of the
hematological counts, and no myeloblasts or MC were seen
in the PB. Unfortunately, the BM aspirate was hypocellular
and results from BM studies were unevaluable. Abdominal
echography revealed stable hepatomegaly (17.5 cm), without
splenomegaly, or adenomegalies. ree months after HSCT
a complete chimerism was documented in PB and BM
neutrophils, monocytes, and lymphocytes. She developed
a chronic graft versus host disease with cutaneous mani-
festations, controlled with cyclosporine A and mycophe-
nolate mofetil. By the time of this report (24 months after
the diagnosis, 15 months after HSCT), she maintains normal
serum tryptase levels, complete hematological remission, and
complete chimerism in PB (Figure 6).
3. Discussion
According to theWHO classication, this complex case fulls
the criteria for the diagnosis of SM-AHN, more precisely,KIT
D816V+ MCL associated with normal karyotype AML [1, 2].
Criteria forMCL include not only the conditions for SM, such
as BM inltration by morphologically and phenotypically
abnormal MC forming dense aggregates (>15 MC), increased
serum tryptase levels (>20 ng/ml), and the KIT (D816V)
mutation in BM cells, but also 16% MC in the BM and 20%
MC in the PB; criteria for AML were more than 20% MPO+
myeloblasts in the BM by cytomorphology. Curiously, FCM
studies showed that the cells of the MC lineage were phe-
notypically heterogeneous, with both aberrant MCP and
more mature MC being identied in the BM, and only the
former being present in the PB. Interestingly, FCM studies
also revealed that the granulocytic cells had an almost
complete blockage at the promyelocyte stage, despite the fact
that t(15;17) was negative. us, the MC and the granulocytic
cell lineages were both compromised by the leukemic process.
In accordance to this multilineage involvement, the KIT
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D816V mutation was found in all BM cell populations tested,
except in T cells. ese ndings are in line with previous
studies, indicating that the occurrence of KITmutations in an
early progenitor cell results multilineage involvement, MC
maturation blockade, immature MC phenotype, and ag-
gressive disease [17–19]. e possibility of a secondary MCL
arising in the context of a previously undiagnosed ISM is
plausible, as the patient had a chronic maculopapular rash
that had never been investigated. Unfortunately, skin biopsies
were not performed, and thus, cutaneous inltration by MC
was not formally documented. It should however be men-
tioned, that secondary MCL usually occurs in patients with
SM-AHN or ASM, and direct evolution from ISM to MCL is
exceptionally rare [20–22].
e clinical and laboratory ndings in patients with sys-
temic MC neoplasms are diverse, depending on the disease
subset and on the individual variability, and they are related to
the release of MCmediators and/or to the inltration of organs
and tissues by the abnormal MC, which ultimately result in
organ damage/failure (C-symptoms) [8, 20–22]. Except for
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Figure 4: Peripheral blood dot plots obtained by ow cytometry showing 3% of CD117+ CD34+ myeloid precursor cells (black dots) and
49% of CD117+ CD34-mast cells precursors (orange dots). Please note that circulating myeloid precursor cells (black dots) and mast cells
precursor (orange dots) had an immunophenotype like that observed in bone marrow (BM) myeloid precursor cells and BM mast cell
precursors, respectively (please cf. Figure 3, same color code). Please also note that the relatively mature mast cells observed in BM (red dots,
Figure 3) were not present in the peripheral blood.
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a lower time from symptoms to diagnosis and a more severe
neutropenia and thrombocytopenia, the clinical features
observed in our patient with MCL+AML did not differ
substantially from those usually found in patients with
other advanced MC neoplasms, such as ASM and SM-
AHN, as described in the largest series of patients with SM
(342 cases), published by Lim et al. in 2009 (Table 1) [20]. In
this series, ISM was the predominant SM subtype (46%),
followed by SM-AHN (40%, subtype not specified) and
ASM (12%), and only 4 cases were MCL (1%).
)e clinical and laboratory features of our patient were
those expected to occur in cases of MCL, as previously de-
scribed in the literature (Table 2). In 2013, Georgin-Lavialle
et al. revised all the MCL cases that had been published in
scientific journals indexed in the MedLine [8]. In total, they
provided data from 51 cases, including a series of 10 cases of
MCL, published by Valentini et al. in 2008 [21], several cases
reported individually from 1950 to 2012, and 4 personal
unpublished cases; in 41 cases, they had enough data to
classify them as de novo MCL (n� 30) or as secondary MCL
(n� 11), and to compare the clinical and biological features
of these entities (Table 2) [8]. Very recently, in 2017, Jawhar
et al. reported on the clinical and laboratorial characteristics
of 28 patients with MCL, from which 12 (43%) had sec-
ondary MCL and 20 (71%) had associated hematological
neoplasms (MCL-AHN), other than AML [22] (Table 2). To
the best of our knowledge, data available in the literature are
not enough to establish if MCL-AHN has worse outcome
(a) (b)
(c) (d)
(e) (f)
Figure 5: Bone marrow trephine biopsy showing a hypercellular marrow (a) with grade 2 fibrosis (b), and a preponderance of myeloid
precursors with a diffuse proliferation of myeloperoxidase+ blast cells (c and d) and CD117+ mast cells (e and f). (a) Hematoxylin and eosin
(H&E) stain, original amplification ×40. (b) Reticulin stain, original magnification ×100. (c) H&E stain, original amplification ×100.
(d) MPO stain, original amplification ×100. (e) H&E stain, original amplification ×100. (f) CD117 stain, original amplification ×100.
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than SM- (other than MCL) AHN, or if the type of AHN is
more important for prognosis.
Rare cases of MCL have been diagnosed previously,
subsequently or concomitantly to AML, as occurring in this
patient [23–25]. Mast cell leukemia-AML cases exhibit a sub-
stantial increase (>20%) in myeloblasts in the BM, and they
must be distinguished from MML where an AML may also be
diagnosed, but criteria for SM are not met (Table 3).
Myelomastocytic leukemia is a very rare type of leukemia
that is not yet incorporated in the WHO classication of the
tumors of lymphoid and hematopoietic tissues [9, 16]. It is
characterized by an expansion (>10%) of atypical MC to-
gether with BC with metachromatic granules (identied as
MC precursors by immunophenotyping) in the BM and/or
PB, concomitantly with criteria for an advanced myeloid
neoplasm, which may have features of AML, MDS with
excess of blast cells, or accelerated/blast phase of a MPN or
a MDS/MPN. By denition, MML carries no specic (re-
current) molecular and immunophenotypic markers for SM.
Specically, activating point mutations at codon 816 of KIT
are not found, and the aberrant CD2+/CD25+ MC
immunophenotype, which is typically found in the majority
of SM cases, is rare in MML. In addition, in patients with
MML, the karyotype usually reects the underlying disease
(e.g., MDS, MPN, MDS/MPN, and AML) and chromosomal
aberrations are frequently complex; in contrast, no recurrent
chromosome abnormalities are known for patients with
MCL [9, 16]. In addition, the neoplastic MC in MCL usually
express CD117, low tryptase, and low FcεRI, and are often
CD25+, whereas in MML, MC also express CD117 and
tryptase, but they habitually stain negative for CD25. CD2 is
usually negative in both cases, being frequently detected in
MC from patients with indolent or smoldering SM (Table 4).
Some other markers, including HLA-DR, CD30, and CD123,
may also be positive inMCL cells, as observed in our patient.
us, the clinical and laboratory ndings observed in this
case would favor the diagnosis of MCL associated to AML,
instead of MML.
Management of patients with AML relies on genetic tests
that allows for the diagnosis, informs about prognosis, and
predicts response to therapy, and the value of genetics is
reinforced in the WHO classication scheme for AML. For
instance, cytogenetic aberrations have long been recognized
as important prognostic variables in AML patients [26].
However, patients with AML and normal karyotype have had
a very heterogeneous outcome, and previous studies have
indicated that many other molecular aberrations do inuence
the response to treatment as well as in the risk of relapse [27].
For example, AML with normal cytogenetics may carry poor
prognostic genetic lesions, such as FLT3 mutations, over-
expression of BAALC (brain and acute leukemia cytoplas-
mic), ERG (ETS/E26 transformation-specic-related gene),
orMN1 (meningioma 1) genes, or they may have aberrations
that predict better prognosis as are cases with isolated
NPM-1 or CEBPA (CCAAT/enhancer binding protein alpha)
mutations [27]. Among them, FLT3 and NPM-1 mutations
were found to be absent in this patient. Also negative were
studies for other relevant targets including t(15;17) PML-
RARA, t(8;21) RUNX1-RUNX1T1, inv(16) CBFB-MYH11,
and t(9,22) BCR-ABL. As mentioned before, SRSF2, ASXL1,
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Figure 6: Serum tryptase levels from diagnosis of MCL-AML to date. Serum tryptase levels were markedly increased at the diagnosis
(184 μg/L, October 2015) and decreased transiently to 41 μg/L after two cycles of cladribine (5 days, with one month of interval: December
2015; January 2016). However, one month later (February 2016), the serum tryptase levels increased again to 123 μg/L, and the BM aspirate
showed 47% myeloblasts. At that time, the patient received two cycles of combined therapy with idarubicin and cytosine arabinoside
(3 + 7 days) (February 2016; April 2016) followed by two cycles of high-dose cytosine arabinoside (June 2016; July 2016). At day +32 of
reinduction chemotherapy (May 2016), the patient achieved complete hematological remission, and the serum tryptase levels decreased to
8mg/L, remaining normal to date. At the end of August 2016, the patient received allogeneic hematopoietic stem cell transplantation
(HSCT) from her sister. By the time of this report (November 2017, 24 months after the diagnosis, 15 months after HSCT), she maintains
a complete hematological remission and a complete chimerism in peripheral blood.
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Table 1: Clinical and laboratory features observed in our patient withMCL+AML, as compared to those described in a series of 342 patients
with SM, including ISM, ASM, and SM-AHN, published by Lim et al. in 2009 [20].
Lim et al. series [20]
)is case (MCL-AML)
ISM (n� 159) ASM (n� 41) SM-AHN (n� 138)
Demographic data
Age, years 49 (19–84) 65 (32–85) 65 (20–87) 41
Gender, males/females 69 (43)/90 (57) 19 (46)/22 (54) 97 (70)/41 (30) Female
Clinical features
Time from symptoms to diagnosis, months 72 (0–516) 18 (1–372) 15 (1–360) 1 month
Maculopapular skin lesions 100 (63) 15 (37) 25 (18) Yes
Cutaneous symptoms 20 (71) 16 (62) 10 (83) Yes
Constitutional symptoms 3 (19) 24 (59) 85 (62) Yes
MC mediators-related symptoms 110 (69) 9 (22) 39 (28) Yes
Anaphylactoid reactions 53 (33) 2 (5) 2 (1) No
Musculoskeletal symptoms 48 (30) 17 (41) 41 (30) No
Gastrointestinal symptoms 113 (71) 26 (63) 79 (57) Yes
Hepatomegaly 22 (14) 16 (39) 53 (38) Yes
Splenomegaly 26 (17) 18 (44) 76 (57) Yes
Lymphadenopathy 22 (14) 11 (27) 40 (29) Yes
C-findings NA 41 (100) 36 (26) Yes
BM dysfunction with cytopenia(s) NA 13 (32) NA Yes
Hepatomegaly with functional impairment NA 11 (27) 20 (14) Yes
Splenomegaly with hypersplenism NA 9 (22) 16 (12) Yes
Osteolysis/pathological fractures NA 18 (44) 5 (4) No
Malabsorption with weight loss NA 2 (5) 1 (1) No
Peripheral blood findings
Hemoglobin, g/dl 13.9 (8.1–16.7) 11.3 (5.1–16.5) 10.9 (6.4–17.4) 11.0
Hemoglobin,<10.0 g/dl 4 (3) 10 (24) 48 (45) No
Platelets, ×109/L 260 (39–570) 179 (20–561) 129 (2–1625) 16
Platelets,<100×109/L 2 (1) 11 (27) 50 (37) Yes
Neutrophils, ×109/L 4.2 (0.6–12.4) 4.2 (0.9–17.8) 4.8 (0.2–42.5) 0.3
Neutrophils,<100×109/L 2 (1) 2 (5) 11 (8) Yes
Serum tryptase, μg/L 53.6 (11.4–1410) 145 (10–2000) 75.4 (3.7–1360) 184
Increased tryptase:>11.5/>200 μg/L 89 (99)/11 (12) 14 (93)/6 (40) 49 (92)/15 (28) >11.5/<200
Decreased albumin (<35 g/L) 10 (9) 10 (26) 29 (27) Yes
Increased AP (>115U/L) 36 (25) 24 (60) 65 (50) Yes
Increased AST (>48)/ALT (>55U/L) 10 (7)/4 (7) 5 (13)/1 (9) 22 (17)/5 (16) Yes
Increased total bilirubin 3 (11) 10 (28) 42 (32) Yes
Increased LDH (>222U/L) 2 (4) 1 (9) 25 (25) Yes
Bone marrow findings
BM cellularity: increased/decreased 49 (32)/15 (10) 24 (67)/3 (8) 123 (91)/1 (1) Increased
MC in BM biopsy: <10% 58 (41) 9 (26) 42 (35) NA
MC in BM biopsy: 10–30%/>30% 68 (48)/15 (11) 17 (50)/8 (24) 66 (55)/12 (10) NA
Fibrosis grade 2 or more 5 (14) 8 (47) 31 (46) Grade 2
MC phenotype, FCM: CD2+/CD25+ 27 (66)/39 (95) 4 (50)/8 (100) 7 (33)/18 (86) No/Yes
MC nuclear morphology: oval/elongated 87 (78)/24 (22) 21 (66)/7 (22) 82 (73)/17 (15) Mixed
MC nuclear morphology: indented/round 0 (0)/0 (0) 3 (9)/1 (3) 10 (9)/3 (3)
Blasts in BM smears: 5–10%/>10% 0 (0)/0 (0) 0 (0)/0 (0) 16 (12)/11 (8) 24%
Molecular and chromosomal aberrancies
KIT D816V mutation (78) (82) (60) Yes
FIP1L1-PDGFRA rearrangement (52) NA NA No
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Table 1: Continued.
Lim et al. series [20]
)is case (MCL-AML)
ISM (n� 159) ASM (n� 41) SM-AHN (n� 138)
JAK2 V617F mutation (4) NA NA NA
Abnormal karyotype (5) (20) (31) No
Survival and leukemic transformation
Transformation into AML or MCL 1 (<1) 2 (5) 18 (13) MCL+AML
Median survival time from diagnosis, mo 198 41 24 Alive, 24 mo
Deaths after median follow-up of 21 mo 26 (16) 25 (61) 99 (72) NA
AHN, associated hematological neoplasm; ALT, alanine transaminase; AML: acute myeloid leukemia; AP, alkaline phosphatase; AST, aspartate transaminase;
BM: bone marrow; FCM, flow cytometry; LDH, lactate dehydrogenase; MC, mast cells; MCL, mast cell leukemia; mo, months; NA, not available, not
evaluated or not applicable. Not all parameters were evaluated in all patients. Results are presented as median (range) values or as number (percentage) of
patients with the mentioned characteristic.
Table 2: Clinical and laboratory features observed in our patient withMCL+AML, as compared to those described in a review of 51 cases of
MCL performed by Georgin-Lavialle et al. in 2013 [8], and in a series of 28 patients with MCL published by Jawhar et al. in 2017 [22].
Georgin-Lavialle et al. review [8] Jawhar et al. series [22]
)is case
(MCL-AML)MCL
(n� 51)
De novo MCL
(n� 30)
Secondary
MCL (n� 11)
MCL
(n� 28)
De novo MCL
(n� 16)
Secondary
MCL (n� 12)
Demographic data
Age, years 52 (5–76) 52 (18–76) 35 (5–75) 67 (45–82) 69 (47–82) 65 (45–73) 41
Gender, males/females 20 (40)/30(60) 11 (38)/18 (62) 6 (55)/5 (45)
16 (57)/12
(43) 10 (63)/6 (37) 6 (50)/6 (50) Female
Diagnosis
MCL (without AHN) 36/40 (90) 27 (89) 11 (100) 8 (29) 6 (38) 2 (17) No
MCL-AHN (other than
AML)∗ 4/40 (10) 3 (11) 0 (0) 20 (71) 10 (62) 10 (83) No
MC disorder prior to
MCL∗∗ 11 (40) 0 (0) 11 (100) 12 (43) 0 (0) 12 (100) Probably yes
ASM NA NA NA 2 (7) 0 (0) 2 (17) No
SM-AHN NA NA NA 10 (36) 0 (0) 10 (83) No
Leukemic MCL (MC in the
PB≥ 10%) 18/47 (38) 15 (50) 3 (30) 2 (7) NA NA Yes (20)
Peripheral blood findings
Tryptase, μg/L 433(21–2357) 433 (21–742) 250 (173–2357)
520
(157–1854) 520 (157–1854)
544
(160–1250) 184 μg/L
Tryptase> 200 μg/L NA NA NA 26 (93) 15 (94) 11 (92) No
Cytopenias NA NA NA 26 (93) 15 (94) 11 (92) Yes
Hemoglobin, gr/dl 9.9(5.4–14.0) 9.0 (5.4–13.7) 11.0 (8.1–13.3)
8.9
(7.9–14.3) 9.2 (7.9–13.3) 8.7 (7.9–14.3) 11.0
Neutrophils, ×109/L 3.7(1.0–15.3) 6.0 (1.0–14) NA NA NA NA 0.3
Platelets, ×109/L 110(5–318) 82 (5–202) 111 (30–150)
69
(21–795) 64 (21–795) 86 (26–331) 16
Hypoalbuminemia< 35 g/L NA NA NA 11 (39) 5 (31) 6 (50) Yes (32 g/L)
Alkaline
phosphatase> 150U/L NA NA NA 20 (71) 10 (62) 10 (62) Yes (731U/L)
% Mast cells 6 (0–72) 7 (0–72) 0 (0–12) NA NA NA 21%
Other relevant findings
Splenomegaly 38/49 (65) 23 (82) 9 (82) 28 (100) 16 (100) 12 (100) Yes
Hepatomegaly 32/47 (68) 21 (78) 6 (60) NA NA NA Yes
Skin lesions 15/50 (30) 4 (14) 5 (45) NA NA NA Yes
Ascites 9/50 (18) 5 (17) 1 (9) 13 (46) 7 (44) 6 (50) Yes
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and RUNX1mutations, described to be present in around 50%
of MCL patients and found to affect adversely response to
treatment and to predict lower OS [22], were not examined in
this case.
Due fundamentally to the extreme rarity of MCL, no
standard treatment exists, and therapies frequently consist on
those commonly used in aggressive SM, such as cladribine
(2-chloro-deoxy-adenosine, 2-CDA), interferon alpha 2a
(IFN-α2a), and tyrosine kinase (TK) inhibitors (TKI). AsMCL
is presumably a clonal disorder of hematopoieticmyeloid stem
cells, chemotherapy with drugs proven successful in AML,
such as anthracyclines in combination with AraC, have also
been used to treat patients with MCL. If hematological re-
mission is achieved, additional therapy with curative intent
involving HSCTmight be attempted, as in this patient [7, 8].
)e rationale behind the use of cladribine, which was the
first therapy tried in our patient, is based on the value of this
drug in the treatment of aggressive SM, which has been
confirmed in several studies [28, 29]. However, 2-CDA had
no or little activity in this case, as in most previously reported
cases of MCL treated with this purine analogue [22, 30],
although in rare cases transient or prolonged partial response
has been observed [21, 31, 32]. Reports on the use of IFN-α2a
in MCL are scarce, and the results obtained were also not
encouraging [21, 31].
Tyrosine kinase inhibitors have been actively investi-
gated for the treatment of patients withmastocytosis because
KIT mutations often cause constitutive activation of TK
activity of the KIT receptor [33]. Imatinib is effective in
patients with increased mast cells and eosinophils associated
Table 2: Continued.
Georgin-Lavialle et al. review [8] Jawhar et al. series [22]
)is case
(MCL-AML)MCL
(n� 51)
De novo MCL
(n� 30)
Secondary
MCL (n� 11)
MCL
(n� 28)
De novo MCL
(n� 16)
Secondary
MCL (n� 12)
Asthenia NA (78) NA NA NA NA NA Yes
Weight loss> 10% in 6
months NA (38) NA NA 12 (43) 8 (50) 4 (33) NA
Anorexia NA (20) NA NA NA NA NA Yes
Flushing and other MCAS 39/50 (78) 24 (83) 8 (73) NA NA NA Yes
Bone marrow findings
% MC in BM smears NA NA NA 25 (20–95) 25 (20–95) 20 (20–95) 16
% MC in BM biopsy 50(20–100) 60 (20–100) 60 (25–90) 65 (20–95) 60 (20–95) 65 (30–95) NA
Phenotypic aberrancies
CD2+ 15/29 (52) 6 (46) 1 NA NA NA No
CD25+ 18/24 (75) 6 (50) 3 NA NA NA Yes
Molecular and
chromosomal aberrancies
KIT D816V mutation 13/28 (46) 6 (40) 1 (20) 16 (68) 10 (63) 9 (75) Yes
Other KITmutations 6/28 (22) 3 (19) 3 (60) 6 (21) 4 (25) 2 (17) NA
SRSF2, ASXL1, or RUNX1
mutations NA NA NA 13 (52) 7 (50) 6 (55) NA
Normal karyotype∗∗∗ 20/23 (83) 8 (73) NA 19 (79) 11 (79) 8 (10) Normal
Survival and leukemic
transformation
Survival, months 6 (0.5–98) 4 (0.5–24) 5 (1–18) 17 (1–86) NA NA >24
Progression into secondary
AML∗∗∗∗ NA NA NA 3 (11) 2 (13) 1 (8) MCL+AML
Deaths 33/48 (69) 24 (83) 5 (62) 18 (64) 10 (63) 8 (67) Alive
AHN, associated hematological neoplasm; AML, acute myeloid leukemia; BM, bone marrow; CEL, chronic eosinophilic leukemia; CM, cytomorphology;
CMML, chronic myelomonocytic leukemia; MC, mast cells; MCAS, mast cell activation-related symptoms; MCL, mast cell leukemia; MCL-AHN, mast cell
leukemia with associated hematological neoplasm; MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic myeloproliferative neoplasm; NA, not
available or not evaluated. Results are presented as median (range) values or as number (percentage) of patients with the mentioned characteristic. Not all
parameters were evaluated in all patients. ∗AHN included MDS (n� 3) and CMML (n� 1) in the Georgin-Lavialle review, and CMML (n� 8), MDS/MPN
unclassifiable (n� 5), MDS (n� 5) or CEL (n� 2) in the Jawhar series. ∗∗Our patient had past history of uninvestigated maculopapular skin lesions and
flushing episodes, and a maculopapular rash at the diagnosis (skin biopsy not performed). ∗∗∗In the Jawhar series, karyotype was available in 24 patients with
MCL (14 patients with de novo MCL and 10 patients with secondary MCL); 5 patients (21%) had an aberrant karyotype (3 patients with de novo MCL, 21%; 2
patients with secondary MCL, 20%), with 3 patients having a complex karyotype (≥3 aberrations) and 2 patients having del(5q) or del(12p), respectively.
Cytogenetic studies were available for 23 of 51 cases reviewed by Georgin-Lavialle et al., and a normal karyotype was found in 83% cases (83%). Two patients
(9%) had a 5q deletion and were diagnosed as havingMCL-MDS, and 2 patients with de novoMCL had t(10;16)(q22;q13q22) and t(8;21)(q22;q22).)us, there
are no recurrent cytogenetic abnormalities in MCL. ∗∗∗∗)ree patients from the Jawhar series progressed into secondary AML 18, 28, and 34 months,
respectively, after the diagnosis of MCL had been established.
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with FIP1L1/PDGFRA (Factor Interacting with PAPOLA
and CPSF/Platelet-derived growth factor receptor A) fusion
gene (e.g., myeloid neoplasm with eosinophilia and rear-
rangement of PDGFRA) [34] or rare patients with SM as-
sociated with KIT mutations outside of exon 17 [30].
However, the results from imatinib and other TKI, such as
masitinib and dasatinib, in MCL and other D816V+ SM have
been disappointing [21, 35–37].
Midostaurin (PKC412), a multitarget TKI, is a promising
agent for patients with advanced SM, as it inhibits the
growth of neoplastic MC exhibiting various mutant forms of
KIT, including KIT D816V [38]. In contrast to other KIT-
targeting drugs, midostaurin also impedes IgE-dependent
release of histamine [39, 40]. Midostaurin has been reported
to be efficacious in patients with advanced SM, including
ASM and MCL [22, 41, 42]. Data from a Phase 2 single-arm
open-label trial (CPKC412D2201), which included 89 with
mastocytosis-related organ damage (16 with aggressive SM,
57 with SM-AHN, and 16 MCL), revealed that treatment
with midostaurin 100mg twice daily resulted in an overall
response rate of 60% with a median duration of response of
24 months and a median overall survival of 29 months [42].
Unfortunately, midostaurin was not yet approved for pa-
tients with advanced SM, including MCL, and the drug was
not available for compassionate use at the time the MCL
was diagnosed in our patient. Brentuximab vedotin has also
been considered for the treatment of patients with advanced
SM. )e results obtained in a small series of 4 patients with
SM have suggested that this anti-CD30 monoclonal
antibody-drug conjugate can induce durable responses with
Table 3: Clinical and laboratory features in our patient as compared to those observed in patients with MCL or MML, as schematized by
Valent et al. in 2014 [9].
Mast cell leukemia (MCL) Myelomastocyticleukemia (MML) )is case (MCL-AML)
Clinical features
Skin lesions Present in a subset of patients Absent Yes (maculopapular rash)
Spleen
involvement/splenomegaly Found in a subset of patients Usually present at diagnosis Yes (13 cm; splenic nodules)
Liver involvement/
hepatomegaly, ascites Often found Usually not found Yes (18.5 cm; cholestasis; ascites)
MC mediators-related
symptoms Frequent Frequent Yes (flushing; diarrhea)
Peripheral blood findings
Serum tryptase (μg/L) Markedly elevated (usually >200;often >500)
Moderately elevated (usually
<100; often <50) 184 μg/L
Circulating MC Present in a subset of patients Present in a subset of patients Yes (CM: 20%); FCM: 21% MCP
Circulating myeloblasts No (except MCL-AHN) Present in a subset of patients Yes (CM: 6%); FCM: 3% MPC
Bone marrow findings
Underlying non-MCmyeloid
neoplasms No (except MCL-AHN) Yes AML (concomitant diagnosis)
Increased myeloblasts No (except MCL-AHN) Almost always seen
Yes (CM: 24% myeloblasts + 17%
promyelocytes); FCM: 12%
MPC+ 34% promyelocytes
MC clusters and sheets in BM
biopsy Yes No Yes
Diffuse MC infiltrate in the
BM biopsy Yes Yes Yes
MC in BM smears ≥20% ≥10% Yes (CM: 16%); FCM: 5% MCP+ 13% MC
Karyotype Normal or abnormal with a fewlesions (except MCL-AHN)∗∗ Usually complex
∗∗ Normal
CD25+ MC Yes No Yes
KIT D816V or other codon
816 mutation Present Not found
Yes (BM mast cells, CD34+
precursors and other myeloid cells)
KITmutations in non-816-
codons Found in a subset of patients Found in a subset of patients Not investigated
AHN, associated hematological neoplasm; AML, acute myeloid leukemia; BM, bone marrow; CM, cytomorphology; FCM, flow cytometry; MC, mast cells;
MCL, mast cell leukemia; MCL-AHN, mast cell leukemia with associated hematological neoplasm; MCP, mast cell precursors; MML, myelomastocytic
leukemia; MPC, myeloid precursor cells. ∗Past history of uninvestigated maculopapular skin lesions and flushing episodes; maculopapular rash at the
diagnosis (skin biopsy not performed). ∗∗In MML, the karyotype usually reflects the nature of the underlying disease, whereas no recurrent chromosome
abnormalities are known for patients with MCL.
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a manageable toxicity profile [43], and a clinical trial in
patients with CD30 positive ASM andMCL is currently going
on in the United States (NCT01807598). )us, midostaurin
and brentuximab vedotin may be considered alternative
adjuvant therapies in case of disease relapse in our patient.
Induction chemotherapy has been used in some patients
with MCL. According to the review performed by Georgin-
Lavialle et al., AML-type chemotherapy was used in 6 of 51
MCL patients reported till 2013; the median survival time
was 7 months, and all patients died between 2 and 29
months, because of disease progression or multiorgan failure
[8]. A few cases of patients with MCL who received HSCT
have also been reported, but sustained remission was not
achieved in any of them [21, 44–46]. Ustun et al. have re-
ported on a retrospective series of 57 patients with SM,
including SM-AHN (n� 38), ASM (n� 7) and MCL (n� 12),
who received allogeneic HSCT either after myeloablative
(n� 36) or nonmyeloablative reduced-intensity (n� 21)
conditioning regimens [47]. Responses were observed in
70% of the patients, with complete remission in 28%.
Twenty-one percent of patients had stable disease, and 9%
had primary refractory disease. )e best responses were
obtained in SM-AHN (AML/MDS), and the worst were
obtained in MCL patients. Overall survival at 3 years was
57% for all patients, 74% for patients with SM-AHN, 43% for
those with ASM, and 17% for those with MCL, and the
strongest risk factor for poor overall survival was MCL.
Survival was also lower in patients receiving nonmyeloablative
compared with myeloablative conditioning regimens and in
patients having progression compared with patients having
stable disease or response. Although allogeneic HSCTmay be
considered a potentially curative treatment for advanced SM,
including MCL, its definitive role needs to be determined by
prospective clinical trials. Our patientmaintains hematological
remission of both diseases (MCL and AML) with complete
chimerism, 15 months after HLA-identical HSCT.
In summary, we described an extremely rare case of an
adult female with KITD816V+ MCL associated with normal
karyotype AML without FLT3 and NPM-1 mutations, who
was refractive to cladribine and who achieved complete
hematological remission after receiving induction chemo-
therapy with idarubicin and AraC, followed by allogeneic
HLA-identical sibling HSCT preceded by a reduced-
intensity conditioning regimen.
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Table 4: Cell molecules expressed in MC from our patient as compared to those usually expressed in the MC from patients with MCL or
MML, as schematized by Valent et al. in 2014 [9].
Markers Normal MC ISM SSM ASM MCL MML )is case
CD34 (HPCA-1) − − − − − − −
CD117 (KIT) + + + + + + +
Tryptase + + + + + + NA
CD33 (Siglec-3) + + + + + + +
CD123 (IL-3RA) − − − +/− +/− − +
CD2 (LFA-2) − +/− +/− −/+ −/+ − −
CD25 (IL-2RA) − + + + + − +
CD30 (Ki1) − −/+ + + + NA +
FcεRI + + + + −/+ (low) − + (low)
HPCA-1, human precursor cell antigen-1; IL-2RA, interleukin-2 receptor alpha chain; IL-3RA, interleukin-3 receptor alpha chain; ISM, indolent
systemic mastocytosis; SSM, smoldering SM; ASM, aggressive SM; MCL, mast cell leukemia; MML, myelomastocytic leukemia; NA, not available. +,
expressed in MCs in almost all (>90% of) cases; +/−, expressed in a majority of MC in a considerable proportion of cases; −/+, expressed in a minority
of MC in a smaller subset of cases; −, not expressed. In a few cases, one of the two markers, either CD2 or CD25, may be expressed in neoplastic MCs in
MML.
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